Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV000575281 | SCV000671798 | uncertain significance | Hereditary cancer-predisposing syndrome | 2019-02-04 | criteria provided, single submitter | clinical testing | The p.K112E variant (also known as c.334A>G), located in coding exon 3 of the RAD50 gene, results from an A to G substitution at nucleotide position 334. The lysine at codon 112 is replaced by glutamic acid, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
| Invitae | RCV000575281 | SCV002169413 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-02-18 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 484663). This sequence change replaces lysine, which is basic and polar, with glutamic acid, which is acidic and polar, at codon 112 of the RAD50 protein (p.Lys112Glu). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with RAD50-related conditions. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt RAD50 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |